A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Sponsor: Takeda
Listed as NCT02655224, this PHASE3 trial focuses on Uterine Fibroids and remains completed. Sponsored by Takeda, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bunkyo-ku, Japan , Ebetsu, Japan , Ibaraki, Japan , Kagoshima, Japan , Matsudo, Japan , Minato-ku, Japan , Nishinomiya, Japan , Osaka, Japan , Sakai, Japan , Sapporo, Japan and 1 more location